

Financial Statements

June 30, 2025 and 2024

Table of Contents June 30, 2025 and 2024

	<u>Page</u>
Independent Auditors' Report	1
Financial Statements	
Statements of Financial Position	3
Statements of Activities and Changes in Net Assets	4
Statements of Cash Flows	5
Notes to Financial Statements	6



Independent Auditors' Report

To the Board of Trustees of Children's Hospital of Pittsburgh Foundation d/b/a UPMC Children's Hospital Foundation

Opinion

We have audited the financial statements of Children's Hospital of Pittsburgh Foundation d/b/a UPMC Children's Hospital Foundation (the Foundation), which comprise the statements of financial position as of June 30, 2025 and 2024, and the related statements of activities and changes in net assets and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Foundation as of June 30, 2025 and 2024, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America (GAAP).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with GAAP, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

Baker Tilly Advisory Group, LP and Baker Tilly US, LLP, trading as Baker Tilly, are members of the global network of Baker Tilly International Ltd., the members of which are separate and independent legal entities. Baker Tilly US, LLP is a licensed CPA firm that provides assurance services to its clients. Baker Tilly Advisory Group, LP and its subsidiary entities provide tax and consulting services to their clients and are not licensed CPA firms.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings and certain internal control-related matters that we identified during the audit.

Pittsburgh, Pennsylvania November 25, 2025

Baker Tilly US, LLP

Statements of Financial Position June 30, 2025 and 2024 (Amounts in Thousands)

	2025	2024		2025	2024
Assets			Liabilities and Net Assets		
Current Assets			Current Liabilities		
Cash and cash equivalents	\$ 4,488	\$ 1,665	Due to UPMC Children's Hospital of Pittsburgh:		
Current portion of pledges receivable	9,890	11,128	Operating expenses	\$ 743	\$ 1,239
Current portion of assets whose use is limited	18,616	19,231	Annual financial support	2,814	2,884
Current portion of investments, donor restricted	6,124	6,478	Accrued expenses	589	
Total current assets	39,118	38,502	Total liabilities	4,146	4,123
Assets Whose Use is Limited, Board Designated	156,342	155,115	Net Assets Without donor restrictions	139,298	158,621
Investments, Donor Restricted	202,096	181,829	With donor restrictions	284,773	245,918
Pledges Receivable, Net	17,169	20,479	Total net assets	424,071	404,539
Beneficial Interest in Charitable Remainder Trusts	376	363			
Beneficial Interest in Perpetual Trusts	13,116	12,374			
Total assets	\$ 428,217	\$ 408,662	Total liabilities and net assets	\$ 428,217	\$ 408,662

Statements of Activities and Changes in Net Assets Years Ended June 30, 2025 and 2024 (Amounts in Thousands)

	2025			2024								
		out Donor trictions		ith Donor strictions	-	Total		out Donor strictions		ith Donor strictions		Total
Revenues and Other Support Contributions and bequests	\$	10,892	\$	29,253	\$	40.145	\$	13,329	\$	29,110	\$	42.439
Interest and dividends, net of fees Contributed services	Ψ	4,759 503	Ψ	4,480	Ψ	9,239	Ψ	4,722 493	Ψ	4,313	Ψ	9,035 493
Change in discount Allowance for doubtful pledges and pledges written off		(67)		816 (409)		749 (409)		70		(942) (18)		(872) (18)
Total revenues and other support before												
net assets released from restrictions		16,087		34,140		50,227		18,614		32,463		51,077
Net assets released from restrictions used for, Annual financial support and other operating expenses	-	10,208		(10,208)			-	24,525		(24,525)		
Total revenues and other support		26,295		23,932		50,227		43,139		7,938		51,077
Expenses Contributions to UPMC Children's Hospital of Pittsburgh,												
Annual financial support and petition requests		34,446		-		34,446		36,691		-		36,691
Fundraising General and administrative		7,523 3,070		-		7,523 3,070		7,372 3,066		-		7,372 3,066
General and administrative												
Total expenses		45,039				45,039		47,129		-		47,129
Increase (decrease) in net assets before other changes in net assets		(18,744)		23,932		5,188		(3,990)		7,938		3,948
Other Changes in Net Assets												
Net realized and unrealized gain on investments Valuation gain, beneficial interest in charitable		15,532		17,488		33,020		15,548		16,810		32,358
remainder trusts		-		13		13		-		24		24
Valuation gain, beneficial interest in perpetual trusts Reclassification of net assets		(000)		742		742		-		889		889
Transfer of net assets		(398) (15,713)		398 (3,718)		- (19,431)		- (7,471)		- (5,992)		- (13,463)
	-	, ,		<u> </u>		, ,						,
Change in net assets		(19,323)		38,855		19,532		4,087		19,669		23,756
Net Assets, Beginning		158,621		245,918		404,539		154,534		226,249		380,783
Net Assets, Ending	\$	139,298	\$	284,773	\$	424,071	\$	158,621	\$	245,918	\$	404,539

See notes to financial statements

Statements of Cash Flows Years Ended June 30, 2025 and 2024 (Amounts in Thousands)

		2025		2024
Cash Flows From Operating Activities				
Change in net assets	\$	19,532	\$	23,756
Adjustments to reconcile change in net assets to net		,		•
cash used in operating activities:				
Provision for doubtful pledges		409		18
Net realized and unrealized gains on investments		(33,020)		(32,358)
Valuation gain, beneficial interest in charitable		,		, ,
remainder trusts		(13)		(24)
Valuation gain, beneficial interest in perpetual trusts		(742)		(889)
Contributions of endowment funds restricted in perpetuity		(3,849)		(4,879)
Changes in assets and liabilities:		(0,010)		(1,010)
Pledges receivable		4,139		(1,305)
Due to UPMC Children's Hospital of Pittsburgh:		1,100		(1,222)
Operating expenses		(496)		96
Annual financial support		(70)		(1,400)
Accrued expenses		589		(93)
, toolada oxponoco	-			(00)
Net cash used in operating activities		(13,521)		(17,078)
Cash Flows Provided by Investing Activities				
Net sales and maturities of investments and				
assets whose use is limited		27,331		4,330
doseto whose doe is inniced		27,001		4,000
Cash Flows Provided by Financing Activities				
Contributions of endowment funds restricted in perpetuity		3,849		4,879
Net change in cash and cash equivalents and restricted				
cash and cash equivalents		17,659		(7,869)
Cash and Cash Equivalents and Restricted Cash and Cash		6.640		44.544
Equivalents, Beginning		6,642		14,511
Cash and Cash Equivalents and Restricted Cash and Cash				
Equivalents, Ending	\$	24,301	\$	6,642
			_	0,0.2
Reconciliation of Cash and Cash Equivalents and Restricted Cash and Cash Equivalents to Statements of Financial Position				
Cash and cash equivalents	\$	4,488	\$	1,665
Cash and cash equivalents included in assets whose use is limited	*	19,813	*	4,977
2 2 2 2		,		.,
Total cash and cash equivalents and				
restricted cash and cash equivalents	\$	24,301	\$	6,642

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

1. Organization

Children's Hospital of Pittsburgh Foundation d/b/a UPMC Children's Hospital Foundation (the Foundation) was created on July 1, 2000, primarily to support the fund-raising and development efforts of the UPMC Children's Hospital of Pittsburgh.

2. Affiliation Agreement

On October 31, 2001, Children's Hospital of Pittsburgh consummated an affiliation with University of Pittsburgh Medical Center (UPMC Health System or UPMC) pursuant to the terms of the Integration and Affiliation Agreement (the Affiliation Agreement) by and among the Children's Hospital of Pittsburgh, the Foundation and UPMC Health System (collectively, the Parties). As a result of the Affiliation Agreement, Children's Hospital of Pittsburgh became UPMC Children's Hospital of Pittsburgh (the Hospital). Under the terms of the Affiliation Agreement, the Foundation was reorganized such that the UPMC Children's Hospital of Pittsburgh was no longer the sole corporate member of the Foundation and the Foundation has no corporate member. The Foundation is structured as a supporting organization of the Hospital.

The terms of the Affiliation Agreement provided that UPMC Health System would construct a new pediatric hospital (the New CHP) for the Hospital. Pursuant to an amendment entered into by the Parties on September 28, 2004, the Foundation was required to provide funding for the New CHP in the amount of \$50,000 (the Initial Funding Commitment). The Initial Funding Commitment was fulfilled upon completion of the New CHP in May 2009.

In January 2007, the Affiliation Oversight Committee approved an increase to the projected cost for the design and construction of the New CHP of \$46,800 and the Foundation agreed in September 2007 to fund the \$46,800 increased project costs (Additional Funding Commitment). The Additional Funding Commitment was fulfilled in October 2013.

The Affiliation Agreement required the Hospital, after receiving Orphan's Court and regulatory approval, to transfer to the Foundation certain unrestricted and restricted investments, as well as the Hospital's beneficial interests in certain perpetual trusts. The Affiliation Agreement requires that the Foundation, for the longer of 20 years or for so long as the Foundation supports the mission of the Hospital, will provide annual financial support equal to 5% of the rolling average corpus of such transferred investments, beneficial interests in certain perpetual trusts and donations received thereafter, unless the original donor specified a different spending provision. This annual funding commitment is conditional upon the Hospital delivering to the Foundation a broad range of funding requests, and to meet certain standards selected by the Parties as indicators of the Hospital's continued or improved performance.

3. Summary of Significant Accounting Policies

Basis of Presentation

The financial statements of the Foundation have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP), including accounting standards as they relate to financial statements of not-for-profit organizations. The Financial Accounting Standards Board's (FASB) guidance requires the reporting of total assets, liabilities and net assets in a statement of financial position; reporting the change in net assets in a statement of activities; reporting the sources and uses of cash and cash equivalents in a statement of cash flows and reporting expenses by natural and functional classification.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

Net assets and revenues, gains, expenses and losses are classified as without donor restriction or with donor restriction based on the existence or absence of donor-imposed restrictions as follows:

Net Assets Without Donor Restrictions - Net assets that are not subject to donor-imposed stipulations. Net assets without donor restrictions may be designated for specific purposes by action of the Board of Trustees (the Board) or may otherwise be limited by contractual agreements with outside parties.

Net Assets With Donor Restrictions - Net assets whose use by the Foundation is subject to donor-imposed stipulations that can be fulfilled by actions of the Foundation pursuant to those stipulations or that expire by the passage of time are reported as net assets with donor restrictions. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, these net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities and changes in net assets as net assets released from donor restrictions. Additionally, funds received as gifts and bequests which have been accepted with the donor stipulation that the principal be maintained intact in perpetuity are reported as net assets with donor restrictions.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Subsequent Events

The Foundation evaluated subsequent events for recognition or disclosure through November 25, 2025, the date the financial statements were available to be issued.

Cash and Cash Equivalents

Cash and cash equivalents include highly liquid investments with an original maturity of three months or less at the date of purchase, excluding assets whose use is limited and investments.

No collateral or security is provided on these investments, other than the insurance on interest bearing deposits per financial institution by the Federal Deposit Insurance Corporation. The Foundation has not experienced any losses from maintaining these accounts in excess of federally insured limits. Management believes it is not subject to significant risks associated with these accounts.

Pledges Receivable

Unconditional pledges to contribute cash and other assets are reported at their estimated fair value at the date the promise is received. Pledges receivable that are expected to be collected within one year are recorded at their net realizable value. Pledges receivable that are expected to be collected in future years are recorded at the present value of estimated net realizable future cash flows. The discount rates used range from 0.88% to 4.58% depending on when the pledge was initially received.

The Foundation annually evaluates the collectability of its pledges receivable and either reserves for or writes off uncollectible pledges when it is determined the pledge is uncollectible.

Conditional promises to give, that is, those with a measurable performance or other barrier, and a right of return, are not included as support until such time as the conditions are substantially met.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

Investments and Assets Whose Use Is Limited

The Foundation's investments are reported in the statements of financial position as follows:

Assets Whose Use is Limited, Board Designated - These investments represent funds where the Board has restricted the use over the corpus, and funds of which the Board retains control and may at its discretion subsequently use for other purposes.

Investments, Donor Restricted - These investments represent primarily endowed funds for which the corpus is restricted and the related investment income is restricted for specifically designated expenditures.

Investments are in equity investments, fixed income investments and alternative investment strategies, including hedge funds and private equity.

Investments with readily determinable fair values and all investments in debt securities are measured at fair value in the statements of financial position. Investment income or loss (including realized and unrealized gains and losses on investments, interest and dividends, net of investment fees) is included in the determination of increase (decrease) in net assets without donor restrictions unless the income is restricted by donor or law. Interest income is recorded as earned on the accrual basis using the effective yield method. Dividends are recorded on the accrual basis based on the ex-dividend date.

The fair value of the Foundation's alternative investments is based on the beginning value of the Foundation's interest in the investment plus actual contributions and allocated investment income or loss less actual distributions and allocated administrative expense. If available, quoted market prices are used to value alternative investments. Securities that have no available quoted market price are presented at estimated fair value as determined by the trustee using the net asset value practical expedient.

Although the Foundation's investments are invested in a variety of financial instruments, the related fair values, as reported in the statements of financial position, are subject to various market risks, including changes in the equity markets, the interest rate environment and economic conditions. Due to the level of risk associated with investment securities and the level of uncertainty related to changes in the fair value of investment securities, it is reasonably possible that the fair value of investments reported in the accompanying statements of financial position could materially change in the near future.

Beneficial Interest in Charitable Remainder Trusts

The Foundation has been designated as the beneficiary of certain charitable remainder trusts created by donors and held by entities other than the Foundation. Under the terms of the trusts, the Foundation will receive a portion of the assets that remain in the trusts when they are terminated, typically upon death of the current beneficiary. Upon being designated as the beneficiary, the Foundation recorded an asset and recognized contribution revenues with donor restrictions. The beneficial interest recorded by the Foundation is measured at the present value of the estimated future cash payments to be distributed to the Foundation. Subsequent changes in fair value are recorded as valuation gains or losses in net assets with donor restrictions.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

Beneficial Interest in Perpetual Trusts

The Foundation has been designated as the beneficiary of certain perpetual trusts created by donors and held by entities other than the Foundation. Under the terms of the trusts, the Foundation will receive a portion of the income earned on trust assets in perpetuity. Upon being designated as the beneficiary, the Foundation recorded an asset and recognized contribution revenues with donor restrictions. The beneficial interest recorded by the Foundation is measured at the fair value of the Foundation's interest in the trust assets. Subsequent changes in fair value are recorded as valuation gains or losses in net assets with donor restrictions.

Donor Restricted Gifts

The Affiliation Agreement provides that all contributions from donors received for the benefit of the Hospital will be recorded and maintained by the Foundation. Contributions are considered to be available for use unless specifically restricted by the donor. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as support with donor restrictions.

Income Tax Status

The Foundation is a not-for-profit organization as described in Section 501(c)(3) of the Internal Revenue Code (IRC), and is exempt from federal taxes on its exempt income under Section 501(a) of the IRC. Accordingly, no provision for federal and state income taxes is recorded.

The Foundation accounts for uncertainty in income taxes using a recognition threshold of more-likely-than-not to be sustained upon examination by the appropriate taxing authority. Measurement of the tax uncertainty occurs if the recognition threshold is met. Management determined there were no tax uncertainties that met the recognition threshold at June 30, 2025 and 2024.

Presentation

Certain accounts in the prior year financial statements have been reclassified to conform with the current year presentation. These reclassifications had no impact on total net assets.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

4. Pledges Receivable

Pledges receivable consist of the following at June 30:

	2025		2024
Pledges due within one year Pledges due in one to five years Pledges due in more than five years	\$	9,890 19,112 121	\$ 11,128 21,384 1,920
Total pledges receivable, gross		29,123	34,432
Less discount to net present value		2,064	 2,825
Total pledges receivable, net		27,059	31,607
Less current portion of pledges receivable		9,890	 11,128
Noncurrent portion of pledges receivable	\$	17,169	\$ 20,479

5. Investments and Assets Whose Use is Limited

Investments and assets whose use is limited consist of the following at June 30:

	 2025	 2024
Cash and cash equivalents	\$ 19,813	\$ 4,977
U.S. government obligations	33,935	30,797
Corporate bonds	19,725	16,419
Mortgage and asset backed obligations	17,264	11,009
Mutual funds:		
International	102,143	109,113
Large-cap	104,232	117,460
Mid-cap	48,890	31,151
Small-cap	20,360	20,786
Alternative investments:		
Private investment partnership funds	12,891	15,565
Distressed debt funds	 3,925	 5,376
Total investments and assets whose use is limited	\$ 383,178	\$ 362,653

Investments and assets whose use is limited are reported in the accompanying statements of financial position as follows:

	2025	2024		
Current portion of assets whose use is limited	\$ 18,616	\$	19,231	
Current portion of investments, donor restricted	6,124		6,478	
Assets whose use is limited, board designated	156,342		155,115	
Investments, donor restricted	202,096		181,829	
Total investments and assets whose use is limited	\$ 383,178	\$	362,653	

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

The current portions of assets whose use is limited and investments are based upon management's estimate of the amounts required to meet the Foundation's annual financial support to the Hospital in the following year.

The Foundation's investments, primarily held with PNC Bank, consist of cash and cash equivalents, mutual funds, corporate bonds, government obligations and certain alternative investments. The fair value of the Foundation's alternative investments have been valued using the net asset value practical expedient in the absence of readily determinable fair values. Management's estimates are based on information provided by the fund managers or the general partners of these investments.

The Foundation's private investment partnership funds and distressed debt fund agreements obligate the Foundation to provide advance funding periodically up to specified levels. The Foundation had unfunded commitments of \$2,387 at June 30, 2025 and \$2,513 at June 30, 2024 to a variety of private equity, natural resources, venture capital and international funds. The Foundation expects these commitments to be funded over the next several years, depending on market conditions.

The Foundation's private investment partnership funds and distressed debt funds cannot be redeemed. Instead, the nature of these investments is that distributions are received through the liquidation of the underlying assets of the funds. The Foundation does have the ability to sell these funds on secondary markets.

Total investment return, net of related investment fees, consists of the following:

	 2025	2024		
Interest and dividends Less investment fees	\$ 9,386 (147)	\$	9,175 (140)	
Interest and dividends, net	9,239		9,035	
Net realized and unrealized gains	 33,020		32,358	
Total investment return	\$ 42,259	\$	41,393	

6. Fair Value Measurements

The Foundation measures its investments and assets whose use is limited, beneficial interest in charitable remainder trusts, and beneficial interest in perpetual trusts at fair value on a recurring basis in accordance with GAAP. Fair value is defined as the price that would be received to sell an asset or the price that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. The framework that the authoritative guidance establishes for measuring fair value includes a hierarchy used to classify the inputs used in measuring fair value. The hierarchy prioritizes the inputs used in determining valuations into three levels. The level in the fair value hierarchy within which the fair value measurement falls is determined based on the lowest level input that is significant to the fair value measurement.

The levels of the fair value hierarchy are as follows:

Level 1 - Fair value is based on unadjusted quoted prices in active markets that are accessible to the Foundation for identical assets. These generally provide the most reliable evidence and are used to measure fair value whenever available.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

Level 2 - Fair value is based on significant inputs, other than Level 1 inputs, that are observable either directly or indirectly for substantially the full term of the asset through corroboration with observable market data. Level 2 inputs include quoted market prices in active markets for similar assets, quoted market prices in markets that are not active for identical or similar assets, and other observable inputs.

Level 3 - Fair value is based on significant unobservable inputs. Examples of valuation methodologies that would result in Level 3 classification include option pricing models, discounted cash flows and other similar techniques.

The following tables present the Foundation's financial instruments measured and reported at fair value at June 30, 2025 and 2024:

	2025							
		Level 1 Level 2		L	evel 3	Tota	Fair Value	
Investments and assets whose use is limited:								
U.S. government obligations Corporate bonds	\$	33,935 19,725	\$		\$	-	\$	33,935 19,725
Mortgage and asset backed obligations		17,264		-		-		17,264
Mutual funds		275,625						275,625
Total		346,549		-		-		346,549
Investments and assets whose use is limited reported at net asset value: Private investment								
partnership funds Distressed debt funds								12,891 3,925
Cash and cash equivalents								19,813
Total investments and assets whose use is limited								383,178
Beneficial interest in charitable remainder trusts		-		-		376		376
Beneficial interest in perpetual trusts						13,116		13,116
Total	\$	346,549	\$		\$	13,492	\$	396,670

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

assets whose use is

\$

336,735

limited

remainder trusts

Total

trusts

Beneficial interest in charitable

Beneficial interest in perpetual

	Level 1		Level 2		L	evel 3	Total Fair Value		
Investments and assets whose use is limited:									
U.S. government obligations	\$	30,797	\$	-	\$	-	\$	30,797	
Corporate bonds Mortgage and asset backed		16,419		-		-		16,419	
obligations		11,009		-		-		11,009	
Mutual funds		278,510						278,510	
Total		336,735		-		-		336,735	
Investments and assets whose use is limited reported at net asset value: Private investment									
partnership funds								15,565	
Distressed debt funds								5,376	
Cash and cash equivalents								4,977	
Total investments and									

2024

362,653

363

12,374

375,390

363

\$

12,374

12,737

Certain investments that were measured at net asset value per share (or its equivalent) have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented in the statements of financial position.

\$

The table below sets forth a summary of certain changes in the fair value of the Foundation's Level 3 assets for the years ended June 30:

			2	025		
	Inter Char Rema	Beneficial Interest in Charitable Remainder Trusts			Total	
Purchases/additions Sales/deductions	\$	13 -	\$	742 -	\$	755 -

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

			2	024		
	Bene	eficial				
	Inter	est in	Ben	eficial		
	Char	itable	Inte	rest in		
	Rema	ainder	Perpetual			
	Trı	usts	Tr	usts	1	Total
Purchases/additions	\$	24	\$	889	\$	913
Sales/deductions		_		_		_

The following is a description of the valuation methodologies used for financial instruments reported at fair value. There have been no changes in methodologies used at June 30, 2025 and 2024.

Corporate bonds, U.S. government obligations, mutual funds and mortgage and asset backed obligations are valued at fair value based on quoted market prices for identical securities in active markets that the Foundation has the ability to access at the measurement date.

The Foundation's private investment partnership funds and distressed debt funds have been valued using the net asset value practical expedient in the absence of readily determinable fair values. Management's estimates are based on information provided by the fund managers or the general partners of these investments.

The private investment partnership funds' investment objective is to seek the preservation of capital and to provide long-term rates of return in excess of the publicly traded markets. The Foundation is invested in eight separate funds invested in a variety of markets, including venture capital, domestic private equity, international private equity and natural resources.

The distressed debt funds' investment objective is to seek the preservation of capital and to provide long-term rates of return comparable to returns generated by top performing domestic fixed income funds. The Foundation is invested in five separate funds invested in a variety of corporate equity and debt instruments.

The beneficial interest in charitable remainder trusts is valued at fair value based on the net present value of the future distributions of the trust assets.

The beneficial interest in perpetual trusts is valued at fair value based on the Foundation's interest in the fair value of the assets held by the trust, which represents a proxy for the discounted present value of future cash flows.

The preceding methods may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Foundation believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

7. Liquidity and Availability of Resources

The following table reflects the Foundation's financial assets available for general expenditure within one year at June 30, 2025 and 2024. Financial assets are considered unavailable when illiquid or not convertible to cash within one year. Unavailable financial assets consist of donor restricted funds not expected to be released from restrictions within the next year, and investments with redemption restrictions.

	2025	 2024	
Financial assets: Cash and cash equivalents Current portion of pledges receivable Current portion of assets whose use is limited Current portion of investments Assets whose use is limited, board designated	\$ 4,488 9,890 18,616 6,124 156,342	\$ 1,665 11,128 19,231 6,478 155,115	
Total financial assets	195,460	193,617	
Less financial assets unavailable for general expenditures within one year: Current portion of pledges receivable whose proceeds are donor restricted Investments with redemption restrictions	(9,232) (16,816)	(8,650) (20,941)	
Total financial assets available to meet cash needs for general expenditures within one year	\$ 169,412	\$ 164,026	

As part of the Foundation's liquidity management, it has a policy to structure its financial assets to be available as its general expenditures, liabilities and other obligations come due. The Foundation invests cash in excess of daily requirements at the discretion of the Board.

8. Net Assets With Donor Restrictions

Net assets with donor restrictions consist of the following at June 30:

	2025	2024	
Restricted for specific purposes: Research Healthcare services and programs	\$ 32,718 162,145	\$ 28,537 133,626	
Total restricted for specific purposes	 194,863	 162,163	
Restricted in perpetuity: Endowment funds Beneficial interest in perpetual trusts Pledges receivable, proceeds to be permanently restricted	71,839 13,116 4,955	67,980 12,374 3,401	
Total restricted in perpetuity	 89,910	 83,755	
Total net assets with donor restrictions	\$ 284,773	\$ 245,918	

The income earned from endowment funds is primarily restricted to support research activities. The income generated from beneficial interests in perpetual trusts is available for operations unless restricted as established by each trust agreement. The restricted purposes as established by certain trusts includes benevolent care and special purpose funds.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

9. Endowment Funds

The Foundation's endowments were established for a variety of purposes and include both donor-restricted endowment funds and funds designated by the Board to function as endowments. As required by FASB authoritative guidance, net assets associated with endowment funds, including funds designated by the Board to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Interpretation of Relevant Law

The Foundation interprets the Commonwealth of Pennsylvania Act 141 (PA Act 141) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. Further it is also the Foundation's interpretation that the PA Act 141 allows for the use of 5% of the fair value of the gift to the extent that the investment return was not sufficient to fund the purpose of the gift during the year. As a result of this interpretation, the Foundation classifies as net assets with donor restrictions to be held in perpetuity: (a) the original value of gifts donated to the endowment; and (b) the original value of subsequent gifts to the endowment. The remaining portion of the donor-restricted endowment fund is classified as net assets with donor restrictions until those amounts are appropriated for expenditure by the Foundation in a manner consistent with the standard of prudence prescribed by PA Act 141.

Endowment Fund Activity

The Foundation's endowment funds consist of the following at June 30:

	2025			2024	
Board designated Available for expenditures for specific purposes Original corpus restricted in perpetuity	\$	3,110 82,784 71,839	\$	2,793 71,942 67,980	
Total endowment funds	\$	157,733	\$	142,715	

The changes in endowment net assets is comprised of the following for the years ended June 30, 2025 and 2024:

	2025									
	Board Designated		Available for Expenditures			tricted in rpetuity		Total		
Endowment net assets, beginning of year	\$	2,793	\$	71,942	\$	67,980	\$	142,715		
Investment return Contributions Reclassifications and other		317		21,968 -		- 3,849		22,285 3,849		
changes Appropriation of endowment assets for expenditures,		-		-		10		10		
annual transfer for operations				(11,126)				(11,126)		
Endowment net assets, end of year	\$	3,110	\$	82,784	\$	71,839	\$	157,733		

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

	_	Board ignated	Available for Expenditures		Restricted in Perpetuity		Total	
Endowment net assets, beginning of year	\$	2,496	\$	61,032	\$	65,092	\$	128,620
Investment return Contributions Reclassifications and other		297 -		21,122 -		- 4,879		21,419 4,879
changes Appropriation of endowment assets for expenditures,		-		-		(1,991)		(1,991)
annual transfer for operations				(10,212)				(10,212)
Endowment net assets, end of year	\$	2,793	\$	71,942	\$	67,980	\$	142,715

Funds With Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or PA Act 141 requires the Foundation to retain as a fund of perpetual duration. In accordance with FASB authoritative guidance deficiencies of this nature that are reported in net assets with donor restrictions were \$0 and \$2 at June 30, 2025 and 2024, respectively.

Return Objectives and Risk Parameters

The investment philosophy of the Foundation is based on a disciplined, consistent and diversified approach utilizing multiple asset classes and multiple managers. The Foundation's intent is to accommodate styles and strategies considered reasonable and prudent. Assets are invested with investment managers who invest in mutual funds, corporate bonds and governmental obligations. Additionally, a portion of the funds are invested in alternative investments which include investments in private investment partnership funds and distressed debt funds. The primary objective is to grow the assets to ensure the Foundation can continue to support the Hospital's operations.

Strategies Employed for Achieving Objectives

To satisfy its long-term rate of return objectives, the Foundation relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Foundation targets a diversified asset allocation that is set by the Foundation's Finance and Investment Committee. The investment assets are invested according to the following asset allocation guideline:

	Current Targets	Long-Term Future Target Range
Domestic large-cap equity Domestic mid to small-cap equity International developed equity Emerging markets Fixed income Hedge funds Private equity	30.00 % 15.00 15.00 15.00 20.00 0.00 5.00	15.00 - 35.00 % 5.00 - 17.50 8.00 - 18.50 8.00 - 18.50 8.00 - 30.00 0.00 - 10.00 0.00 - 15.00

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

Spending Policy and How the Investment Objectives Relate to Spending Policy

PA Act 141 states that provided an organization adopts and follows an investment policy seeking a total return for the assets held, the organization may annually select a spending percentage between 2% and 7% of the three year average fair market value of the assets held by an organization.

The Affiliation Agreement requires that the Foundation will provide annual financial support equal to 5% of the rolling 12 quarter average of the corpus (defined as the value of all of the Foundation's assets less any funds held by the Foundation where the donor has directed a different spending provision). Such calculation includes the endowment funds. Any shortfalls of earnings may be made from excess earnings in prior years.

10. Related-Party Transactions

Annual Financial Support

The Foundation entered into an agreement to provide annual financial support to the Hospital (Note 2). The Foundation provided annual financial support of \$34,446 in 2025 and \$36,691 in 2024. Amounts owed to the Hospital under this agreement were \$2,814 at June 30, 2025 and \$2,884 at June 30, 2024.

Operating Expenses

Certain expenditures, primarily operating expenses, are paid by the Hospital and subsequently reimbursed by the Foundation. Accounts payable relating to these transactions were \$743 at June 30, 2025 and \$1,239 at June 30, 2024.

Contributed Services

The Foundation entered into a lease agreement with the Hospital in 2019. Under the agreement, the Hospital agreed to provide office space to the Foundation beginning December 1, 2019. The lease renews annually at the discretion of the Hospital and the Foundation through December 31, 2029.

The Hospital contributed \$503 and \$493 of office space to the Foundation in 2025 and 2024, respectively. Expenses related to these contributed services are included in general and administrative expenses in the statements of activities and changes in net assets. The contributed services are valued using the agreement between the Hospital and the third-party company. The contributed services did not have any donor restrictions.

Conditional Promise to Give

The Board has approved a conditional promise to give to the Hospital, in an amount up to \$30,000 to support existing and future research initiatives. The funding will be provided as the Hospital incurs the expenses and submits requests for funding to the Foundation. To the extent they are available, donor restricted funds will be used to satisfy this promise to give. Any remaining amounts will be funded using net assets without donor restrictions. The funding was available over the five year period ended in January 2025. The Foundation transferred \$7,932 and \$6,210 to the Hospital under this agreement for the years ended June 30, 2025 and 2024, respectively. The Foundation has transferred a total of \$30,956 towards the \$30,000 goal at June 30, 2025.

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

The Board has approved a conditional promise to give to the Hospital, in an amount up to \$40,700 to support capital expenditures for the Heart Institute at UPMC Children's Hospital. The funding will be provided as the Hospital incurs the expenses and submits requests for funding to the Foundation on an annual basis starting in July 2023. To the extent they are available, donor restricted funds will be used to satisfy this promise to give. Any remaining amounts will be funded using net assets without donor restrictions. The Heart Institute program anticipates seeing its first patients in June 2026, and completion of all phases of the project is expected to occur in March 2027. The Foundation expects to make its final payment to the Hospital related to this conditional promise to give in June 2026. The Foundation transferred \$18,861 and \$11,384 to the Hospital under this agreement for the years ended June 30, 2025 and 2024, respectively. The Foundation has transferred a total of \$30,245 towards the \$40,700 goal at June 30, 2025.

11. Functional Expenses

The Foundation's primary purpose is to support the fundraising and development efforts of the New CHP. Expenses by functional classification consist of the following for the years ended June 30, 2025 and 2024:

	2025							
	Program Fundra		ndraising	General and Administrative			Total	
Salaries and wages Employee benefits and payroll	\$	-	\$	3,763	\$	1,533	\$	5,296
taxes		-		991		189		1,180
Contracted services and professional fees		-		1,717		401		2,118
Office supplies and expenses		-		104		402		506
Event expenses		-		492		-		492
Other expenses Contributions to UPMC Children's Hospital of Pittsburgh, annual financial		-		456		545		1,001
support and petition requests		34,446						34,446
Total	\$	34,446	\$	7,523	\$	3,070	\$	45,039

Notes to Financial Statements June 30, 2025 and 2024 (Amounts in Thousands)

2024

Pr	ogram	Fundraising		General and Administrative		Total	
\$	-	\$	3,494	\$	1,513	\$	5,007
	-		770		335		1,105
	-		2,085		209		2,294
	-		124		368		492
	-		471		-		471
	-		428		641		1,069
							·
	36 691		_		_		36,691
	22,001				_	-	22,001
\$	36,691	\$	7,372	\$	3,066	\$	47,129
		- - - - - 36,691	\$ - \$	\$ - \$ 3,494 - 770 - 2,085 - 124 - 471 - 428	Program Fundraising Admin \$ - \$ 3,494 \$ - 770 - 2,085 - 124 - 471 - 428 36,691 - -	Program Fundraising Administrative \$ - \$ 3,494 \$ 1,513 - 770 335 - 2,085 209 - 124 368 - 471 - - 428 641	Program Fundraising Administrative \$ - \$ 3,494 \$ 1,513 \$ - 770 335